Novo Nordisk A/S B (OP: NONOF )

127.05 -4.15 (-3.16%)

Streaming Delayed Price Updated: 3:53 PM EDT, Jul 26, 2024 Add to My Watchlist

Price and Volume

Volume	4,846
Open	123.65
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	131.20
Today's Range	123.24 - 131.25
52wk Range	86.75 - 201.98
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition

June 24, 2024

The greater weight loss in women did not result in significantly better improvements in heart failure symptoms.

Via Benzinga

Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss

June 21, 2024

As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide.

Via Benzinga

Performance

YTD	+25.54%	+25.54%
1 Month	-14.70%	-14.70%
3 Month	+2.87%	+2.87%
6 Month	+21.46%	+21.46%
1 Year	-20.34%	-20.34%

More News

The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash

June 07, 2024

Via InvestorPlace

Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments

May 14, 2024

Via Benzinga

7 Mutual Funds That Will Outperform in Any Market

February 03, 2024

Via InvestorPlace

Did Ozempic Play A Role In A Man's Suicide? Family Seeks Warning Label

September 11, 2023

Via Benzinga

Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector

November 23, 2023

Via Benzinga

Experts Weigh In On Ozempic's Evolving Side Effects And How To Handle Them

October 09, 2023

Via Benzinga

Diabetes Drug Ozempic May Hold Key to Breaking Addictions: The Guardian

July 03, 2023

Via Benzinga

Icannex Taps Ex Pfizer, FDA & Regulatory Affairs Expert

August 17, 2022

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.